The Residual Stress Relaxation Behavior of Weldments During Cyclic Loading

Accurate measurement of residual stress is necessary to obtain reliable predictions of fatigue lifetime and enable estimation of time-to-facture for any given stress level. In this article, relaxation of welding residual stresses as a function of cyclic loading was documented on three common steels: AISI 1008, ASTM A572, and AISI 4142. Welded specimens were subjected to cyclic bending (R = 0.1) at different applied stresses, and the residual stress relaxation existing near the welds was measured as a function of cycles. The steels exhibited very different stress relaxation behaviors during cyclic loadings, which can be related to the differences in the microstructures of the specimens. A phenomenological model, which treats dislocation motion during cyclic loading as being analogous to creep of dislocations, is proposed for estimation of the residual stress relaxation

The delivery of personalised, precision medicines via synthetic proteins

Introduction: The design of advanced drug delivery systems based on synthetic and su-pramolecular chemistry has been very successful. Liposomal doxorubicin (Caelyx®), and liposomal daunorubicin (DaunoXome®), estradiol topical emulsion (EstrasorbTM) as well as soluble or erodible polymer systems such as pegaspargase (Oncaspar®) or goserelin acetate (Zoladex®) represent considerable achievements. The Problem: As deliverables have evolved from low molecular weight drugs to biologics (currently representing approximately 30% of the market), so too have the demands made of advanced drug delivery technology. In parallel, the field of membrane trafficking (and endocytosis) has also matured. The trafficking of specific receptors i.e. material to be recycled or destroyed, as well as the trafficking of protein toxins has been well characterized. This, in conjunction with an ability to engineer synthetic, recombinant proteins provides several possibilities. The Solution: The first is using recombinant proteins as drugs i.e. denileukin diftitox (Ontak®) or agalsidase beta (Fabrazyme®). The second is the opportunity to use protein toxin architecture to reach targets that are not normally accessible. This may be achieved by grafting regulatory domains from multiple species to form synthetic proteins, engineered to do multiple jobs. Examples include access to the nucleocytosolic compartment. Herein the use of synthetic proteins for drug delivery has been reviewed